Commercialization & investment in biotechnology are key forces transforming laboratory discoveries into real-world applications that benefit health, industry, and the environment. This domain bridges the gap between research innovation and market readiness, involving intellectual property strategies, regulatory navigation, and business model development. Investors, venture capitalists, and corporate partners play a crucial role in funding early-stage biotech startups, clinical trials, and manufacturing scale-up. Commercialization & Investment in Biotechnology also include public-private partnerships and technology transfer offices that support licensing and entrepreneurship. As competition intensifies, strategic alliances and investor confidence hinge on strong scientific validation, scalable platforms, and clear regulatory pathways. This process not only accelerates product development but ensures that scientific breakthroughs reach patients, consumers, and industries worldwide.
Title : Improving health in over 40,000 patients: The impact of nanomedicine fighting antibiotic resistant infections
Thomas J Webster, Brown University, United States
Title : Advancement in dual lateral flow immunoassay design for sensitive, rapid detection of rotavirus and adenovirus in stool samples
Ayan Ahmed Isse, Genexus Biotech Company, Somalia
Title :
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico
Title : Renewed novel biotech ideas, with bioreactor bioengineering economic impact
Murray Moo Young, University of Waterloo, Canada
Title : Osmotic lysis–driven Extracellular Vesicle (EV) engineering
Limongi Tania, University of Turin, Italy
Title : Diversity analyses of microbial communities in Armanis gold-polymetallic mine and acid mine drainage: Bioremediation
Anna Khachatryan, SPC Armbiotechnology of NAS of Armenia, Armenia